Globus Medical (GMED) Competitors

Globus Medical logo
$67.32 -1.28 (-1.87%)
As of 03:14 PM Eastern
This is a fair market value price provided by Massive. Learn more.

GMED vs. MMSI, VCYT, WST, GEHC, and RMD

Should you buy Globus Medical stock or one of its competitors? Globus Medical's main competitors and comparable companies include Merit Medical Systems (MMSI), Veracyte (VCYT), West Pharmaceutical Services (WST), GE HealthCare Technologies (GEHC), and ResMed (RMD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does Globus Medical compare to Merit Medical Systems?

Merit Medical Systems (NASDAQ:MMSI) and Globus Medical (NYSE:GMED) are both mid-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, valuation, earnings, dividends and media sentiment.

99.7% of Merit Medical Systems shares are held by institutional investors. Comparatively, 95.2% of Globus Medical shares are held by institutional investors. 0.7% of Merit Medical Systems shares are held by insiders. Comparatively, 18.4% of Globus Medical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Globus Medical has a net margin of 17.76% compared to Merit Medical Systems' net margin of 9.94%. Globus Medical's return on equity of 14.43% beat Merit Medical Systems' return on equity.

Company Net Margins Return on Equity Return on Assets
Merit Medical Systems9.94% 14.12% 8.37%
Globus Medical 17.76%14.43%12.52%

Merit Medical Systems has a beta of 0.56, suggesting that its share price is 44% less volatile than the broader market. Comparatively, Globus Medical has a beta of 0.98, suggesting that its share price is 2% less volatile than the broader market.

In the previous week, Merit Medical Systems had 1 more articles in the media than Globus Medical. MarketBeat recorded 8 mentions for Merit Medical Systems and 7 mentions for Globus Medical. Merit Medical Systems' average media sentiment score of 0.54 beat Globus Medical's score of 0.26 indicating that Merit Medical Systems is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Merit Medical Systems
3 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Globus Medical
2 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

Merit Medical Systems presently has a consensus price target of $105.91, suggesting a potential upside of 25.47%. Globus Medical has a consensus price target of $96.08, suggesting a potential upside of 40.14%. Given Globus Medical's stronger consensus rating and higher possible upside, analysts plainly believe Globus Medical is more favorable than Merit Medical Systems.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Merit Medical Systems
0 Sell rating(s)
5 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.62
Globus Medical
0 Sell rating(s)
7 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.63

Globus Medical has higher revenue and earnings than Merit Medical Systems. Globus Medical is trading at a lower price-to-earnings ratio than Merit Medical Systems, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Merit Medical Systems$1.52B3.34$128.49M$2.6631.73
Globus Medical$2.94B3.09$537.87M$4.0716.85

Summary

Globus Medical beats Merit Medical Systems on 11 of the 16 factors compared between the two stocks.

How does Globus Medical compare to Veracyte?

Veracyte (NASDAQ:VCYT) and Globus Medical (NYSE:GMED) are both mid-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership and risk.

Globus Medical has higher revenue and earnings than Veracyte. Veracyte is trading at a lower price-to-earnings ratio than Globus Medical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Veracyte$517.15M3.91$66.35M$1.5516.15
Globus Medical$2.94B3.09$537.87M$4.0716.85

95.2% of Globus Medical shares are owned by institutional investors. 1.6% of Veracyte shares are owned by insiders. Comparatively, 18.4% of Globus Medical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Veracyte has a net margin of 21.80% compared to Globus Medical's net margin of 17.76%. Globus Medical's return on equity of 14.43% beat Veracyte's return on equity.

Company Net Margins Return on Equity Return on Assets
Veracyte21.80% 8.99% 8.34%
Globus Medical 17.76%14.43%12.52%

In the previous week, Globus Medical had 4 more articles in the media than Veracyte. MarketBeat recorded 7 mentions for Globus Medical and 3 mentions for Veracyte. Veracyte's average media sentiment score of 0.52 beat Globus Medical's score of 0.26 indicating that Veracyte is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Veracyte
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Globus Medical
2 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

Veracyte presently has a consensus price target of $44.50, suggesting a potential upside of 77.72%. Globus Medical has a consensus price target of $96.08, suggesting a potential upside of 40.14%. Given Veracyte's higher probable upside, equities analysts plainly believe Veracyte is more favorable than Globus Medical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Veracyte
1 Sell rating(s)
5 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.42
Globus Medical
0 Sell rating(s)
7 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.63

Veracyte has a beta of 1.98, indicating that its stock price is 98% more volatile than the broader market. Comparatively, Globus Medical has a beta of 0.98, indicating that its stock price is 2% less volatile than the broader market.

Summary

Globus Medical beats Veracyte on 11 of the 17 factors compared between the two stocks.

How does Globus Medical compare to West Pharmaceutical Services?

West Pharmaceutical Services (NYSE:WST) and Globus Medical (NYSE:GMED) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, analyst recommendations, dividends, earnings, risk, valuation and institutional ownership.

Globus Medical has lower revenue, but higher earnings than West Pharmaceutical Services. Globus Medical is trading at a lower price-to-earnings ratio than West Pharmaceutical Services, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
West Pharmaceutical Services$3.07B9.00$493.70M$8.9144.57
Globus Medical$2.94B3.09$537.87M$4.0716.85

West Pharmaceutical Services has a beta of 1.13, indicating that its share price is 13% more volatile than the broader market. Comparatively, Globus Medical has a beta of 0.98, indicating that its share price is 2% less volatile than the broader market.

93.9% of West Pharmaceutical Services shares are held by institutional investors. Comparatively, 95.2% of Globus Medical shares are held by institutional investors. 0.6% of West Pharmaceutical Services shares are held by insiders. Comparatively, 18.4% of Globus Medical shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Globus Medical had 1 more articles in the media than West Pharmaceutical Services. MarketBeat recorded 7 mentions for Globus Medical and 6 mentions for West Pharmaceutical Services. West Pharmaceutical Services' average media sentiment score of 0.86 beat Globus Medical's score of 0.26 indicating that West Pharmaceutical Services is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
West Pharmaceutical Services
3 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Globus Medical
2 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

West Pharmaceutical Services presently has a consensus target price of $424.67, suggesting a potential upside of 6.93%. Globus Medical has a consensus target price of $96.08, suggesting a potential upside of 40.14%. Given Globus Medical's higher probable upside, analysts clearly believe Globus Medical is more favorable than West Pharmaceutical Services.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
West Pharmaceutical Services
0 Sell rating(s)
1 Hold rating(s)
13 Buy rating(s)
0 Strong Buy rating(s)
2.93
Globus Medical
0 Sell rating(s)
7 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.63

West Pharmaceutical Services has a net margin of 18.81% compared to Globus Medical's net margin of 17.76%. West Pharmaceutical Services' return on equity of 21.78% beat Globus Medical's return on equity.

Company Net Margins Return on Equity Return on Assets
West Pharmaceutical Services18.81% 21.78% 15.99%
Globus Medical 17.76%14.43%12.52%

Summary

West Pharmaceutical Services beats Globus Medical on 11 of the 17 factors compared between the two stocks.

How does Globus Medical compare to GE HealthCare Technologies?

GE HealthCare Technologies (NASDAQ:GEHC) and Globus Medical (NYSE:GMED) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, risk, analyst recommendations, earnings, dividends and institutional ownership.

GE HealthCare Technologies currently has a consensus target price of $82.52, suggesting a potential upside of 0.77%. Globus Medical has a consensus target price of $96.08, suggesting a potential upside of 40.14%. Given Globus Medical's stronger consensus rating and higher possible upside, analysts clearly believe Globus Medical is more favorable than GE HealthCare Technologies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
GE HealthCare Technologies
0 Sell rating(s)
11 Hold rating(s)
12 Buy rating(s)
0 Strong Buy rating(s)
2.52
Globus Medical
0 Sell rating(s)
7 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.63

GE HealthCare Technologies has higher revenue and earnings than Globus Medical. Globus Medical is trading at a lower price-to-earnings ratio than GE HealthCare Technologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GE HealthCare Technologies$20.63B1.80$2.08B$4.7417.28
Globus Medical$2.94B3.09$537.87M$4.0716.85

Globus Medical has a net margin of 17.76% compared to GE HealthCare Technologies' net margin of 9.96%. GE HealthCare Technologies' return on equity of 20.45% beat Globus Medical's return on equity.

Company Net Margins Return on Equity Return on Assets
GE HealthCare Technologies9.96% 20.45% 5.97%
Globus Medical 17.76%14.43%12.52%

GE HealthCare Technologies has a beta of 0.65, indicating that its stock price is 35% less volatile than the broader market. Comparatively, Globus Medical has a beta of 0.98, indicating that its stock price is 2% less volatile than the broader market.

In the previous week, GE HealthCare Technologies had 11 more articles in the media than Globus Medical. MarketBeat recorded 18 mentions for GE HealthCare Technologies and 7 mentions for Globus Medical. GE HealthCare Technologies' average media sentiment score of 0.80 beat Globus Medical's score of 0.26 indicating that GE HealthCare Technologies is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
GE HealthCare Technologies
8 Very Positive mention(s)
3 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Globus Medical
2 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

82.1% of GE HealthCare Technologies shares are held by institutional investors. Comparatively, 95.2% of Globus Medical shares are held by institutional investors. 0.4% of GE HealthCare Technologies shares are held by company insiders. Comparatively, 18.4% of Globus Medical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Globus Medical beats GE HealthCare Technologies on 9 of the 17 factors compared between the two stocks.

How does Globus Medical compare to ResMed?

ResMed (NYSE:RMD) and Globus Medical (NYSE:GMED) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends.

ResMed presently has a consensus target price of $253.69, suggesting a potential upside of 6.98%. Globus Medical has a consensus target price of $96.08, suggesting a potential upside of 40.14%. Given Globus Medical's stronger consensus rating and higher possible upside, analysts clearly believe Globus Medical is more favorable than ResMed.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ResMed
0 Sell rating(s)
11 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.39
Globus Medical
0 Sell rating(s)
7 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.63

ResMed has a net margin of 27.79% compared to Globus Medical's net margin of 17.76%. ResMed's return on equity of 26.42% beat Globus Medical's return on equity.

Company Net Margins Return on Equity Return on Assets
ResMed27.79% 26.42% 19.43%
Globus Medical 17.76%14.43%12.52%

In the previous week, ResMed had 2 more articles in the media than Globus Medical. MarketBeat recorded 9 mentions for ResMed and 7 mentions for Globus Medical. ResMed's average media sentiment score of 0.65 beat Globus Medical's score of 0.26 indicating that ResMed is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
ResMed
8 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Globus Medical
2 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

ResMed has a beta of 0.77, indicating that its stock price is 23% less volatile than the broader market. Comparatively, Globus Medical has a beta of 0.98, indicating that its stock price is 2% less volatile than the broader market.

ResMed has higher revenue and earnings than Globus Medical. Globus Medical is trading at a lower price-to-earnings ratio than ResMed, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ResMed$5.65B5.90$1.52B$10.9821.60
Globus Medical$2.94B3.09$537.87M$4.0716.85

55.0% of ResMed shares are held by institutional investors. Comparatively, 95.2% of Globus Medical shares are held by institutional investors. 0.6% of ResMed shares are held by company insiders. Comparatively, 18.4% of Globus Medical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

ResMed beats Globus Medical on 10 of the 17 factors compared between the two stocks.

Get Globus Medical News Delivered to You Automatically

Sign up to receive the latest news and ratings for GMED and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GMED and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GMED vs. The Competition

MetricGlobus MedicalHealthcare Equipment & Supplies IndustryHealthcare SectorNYSE Exchange
Market Cap$8.90B$5.79B$7.46B$20.58B
Dividend YieldN/A1.69%2.48%3.87%
P/E Ratio16.5138.3332.5328.05
Price / Sales2.845.198.103.55
Price / Cash11.2323.4220.7215.35
Price / Book1.864.064.323.42
Net Income$537.87M$142.56M$3.51B$1.07B
7 Day Performance-6.52%-6.68%-7.64%-6.64%
1 Month Performance-14.77%-8.20%-10.10%-6.69%
1 Year Performance-18.19%-1.92%-2.55%3.06%

Globus Medical Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GMED
Globus Medical
3.5881 of 5 stars
$67.32
-1.9%
$96.08
+42.7%
-18.2%$8.90B$3.14B16.516,000
MMSI
Merit Medical Systems
3.9279 of 5 stars
$88.42
+1.4%
$105.55
+19.4%
+0.9%$5.43B$1.52B33.247,500
VCYT
Veracyte
3.3 of 5 stars
$25.92
+7.3%
$48.40
+86.7%
-37.3%$4.22B$517.15M34.55755
WST
West Pharmaceutical Services
4.1956 of 5 stars
$413.30
+3.4%
$424.67
+2.7%
+53.8%$28.48B$3.07B46.3910,800
GEHC
GE HealthCare Technologies
3.7176 of 5 stars
$84.03
+2.0%
$80.87
-3.8%
+13.2%$38.80B$20.63B17.7354,000

Related Companies and Tools


This page (NYSE:GMED) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners